Aurora Spine announced positive interim results from a clinical study using the ZIP™ MIS Interspinous Fusion System. The study seeks to determine the utility of using interspinous fusion devices as a fusion therapy for the treatment of lumbar spinal stenosis.
Results of interim 3-month analysis included 54 patients, of which 82% reported improvement as a result of the procedure, while 65% of the patients demonstrated clinical meaningful improvement in their pain and function. Use of the ZIP device was observed to be both effective and safe at 3-month follow-up. This study remains active and enrollment is continuing, with more follow-up data expected in the future as more patient data is compiled.
Trent Northcutt, President and Chief Executive Officer of Aurora Spine, commented, “We look forward to additional results published at the 12-month collection point and believe it will continue to trend positively for our physicians and their patients.”
Aurora Spine announced positive interim results from a clinical study using the ZIP™ MIS Interspinous Fusion System. The study seeks to determine the utility of using interspinous fusion devices as a fusion therapy for the treatment of lumbar spinal stenosis.
Results of interim 3-month analysis included 54 patients, of which 82% reported...
Aurora Spine announced positive interim results from a clinical study using the ZIP™ MIS Interspinous Fusion System. The study seeks to determine the utility of using interspinous fusion devices as a fusion therapy for the treatment of lumbar spinal stenosis.
Results of interim 3-month analysis included 54 patients, of which 82% reported improvement as a result of the procedure, while 65% of the patients demonstrated clinical meaningful improvement in their pain and function. Use of the ZIP device was observed to be both effective and safe at 3-month follow-up. This study remains active and enrollment is continuing, with more follow-up data expected in the future as more patient data is compiled.
Trent Northcutt, President and Chief Executive Officer of Aurora Spine, commented, “We look forward to additional results published at the 12-month collection point and believe it will continue to trend positively for our physicians and their patients.”
Copy to clipboard 
